Mechanistically, PEBP4 knockdown led to activation of the extracellular signalregulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4. We identified PEBP4 as a novel regulator mediating human glioma cell proliferation, invasion, and apoptosis as well as tumor formation and growth. Therefore, PEBP4 may be a potential therapeutic target in human glioma treatment.
Phosphatidylethanolamine (PE)-binding protein 4 (PEBP4) is an antiapoptotic protein
that is aberrantly expressed in various malignancies. We previously demonstrated that PEBP4 expression is dramatically induced in human gliomas and positively correlated with tumor grade and patient survival. However, the function of PEBP4 in human glioma development and underlying mechanisms remain largely unknown. By stable lentiviral vector-mediated silencing of PEBP4, we examined the effects of PEBP4 knockdown on the growth, apoptosis, and invasion of U251 and U373 human glioma cell lines using MTT, Transwell, colony formation, and flow cytometric assays. We examined the in vivo role of PEBP4 in tumor growth by inoculation of BALB/c nu/nu male mice with PEBP4-deficient U251 and U373 cells. The expression of cell cycle-and apoptosis-related proteins was analyzed by Western blotting and immunostaining. Knockdown of PEBP4 significantly reduced the proliferation and invasion of human glioma cells while inducing cell apoptosis by altering the expression of cell cycle-and apoptosis-related proteins.
Mechanistically, PEBP4 knockdown led to activation of the extracellular signalregulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4. We identified PEBP4 as a novel regulator mediating human glioma cell proliferation, invasion, and apoptosis as well as tumor formation and growth. Therefore, PEBP4 may be a potential therapeutic target in human glioma treatment.
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| INTRODUCTION
Glioma, the most prevalent type of primary tumor diagnosed in the central nervous system, accounts for approximately 50% of malignant brain tumors and has high rates of recurrence and morbidity. 1 Despite recent advances in standard treatment options, including surgery, radiation therapy, and chemotherapy, the median overall survival in glioma patients remains as low as 28 months. [2] [3] [4] Identifying new potential targets for further development of novel therapeutic options is urgently required for the management of this aggressive type of malignancy. 5, 6 Phosphatidylethanolamine (PE)-binding protein 4 (PEBP4) belongs to the PE-binding protein (PEBP) family, which shares a common PEbinding motif that accommodates different anions such as a phosphoryl group. 7 One member of the PEBP family is RAF kinase inhibitory protein (RKIP)/PEBP1, which binds to RAF1 through the PE-binding motif and playing an important role in tumor formation and progression. [14] [15] [16] [17] Our previous study revealed that PEBP4 expression is significantly upregulated in human glioma compared with normal brain tissue, and immunohistochemistry analysis indicated that PEBP4 expression is positively correlated with the tumor grade and prognosis in patients with gliomas, suggesting a possible involvement of PEBP4 in the tumorigenesis and progression of glioma. 17 Since the PE-binding motif is the hallmark of all PEBP family members and is essential for the inhibitory effect of RKIP/PEBP1 on the RAF-MEK-ERK signaling pathway, 18 we hypothesized that the function of PEBP4 in glioma is associated with ERK1/2 signaling.
In the present study, we examined the role of PEBP4 in glioma cell 
| Transwell invasion assay

| Immunohistochemical staining
Tumors were harvested immediately after mice were sacrificed. After sectioning, 5-µm-thick paraffin-embedded tumor tissue sections were processed for deparaffinization/rehydration and antigen retrieval. To examine the expression of PEBP4 in U251 and U373 cell-derived tumor tissues, sections were blocked in 10% goat serum for 1 h and incubated overnight with goat anti-human PEBP4 primary antibody Tumors were immediately harvested and weighed.
| Statistical analysis
All data are representative of at least three independent experiments.
Data are expressed as the mean ± SD and were graphed with 
| PEBP4 knockdown inhibits glioma cell proliferation and invasive potential
To explore the function of PEBP4 in human glioma cells, we successfully used a lentiviral vector expressing PEBP4 shRNA (Lenti-shPEBP4) to dramatically and stably silence PEBP4 expression in the U251 and U373 glioma cell lines. As shown in Figures 1A and 1B, lenti-shPEBP4-2 and -3 induced the highest degrees of PEBP4 silencing in U251 and U373 cells, respectively, compared with control lentiviral vectors expressing GFP (Lenti-GFP). These two lentiviral vectors were used in the subsequent experiments.
We next sought to examine the effect of PEBP4 silencing on glioma cell proliferation. As shown in Figure 2A , knockdown of PEBP4 significantly inhibited U251 and U373 cell proliferation in a timedependent manner, compared with that of the control groups, including non-transfected (Con) and Lenti-GFP-transfected cells. In addition, a colony formation assay was performed to determine the effect of PEBP4 knockdown on the anchorage-independent growth ability of glioma cells, a key feature of glioma metastasis. As shown in FIGURE 2 PEBP4 knockdown suppressed glioma cell proliferation, invasion, and colony formation in vitro. A, MTT, (B) colony formation, and (C) transwell assays were performed to examine the effects of PEBP4 knockdown on proliferation, anchorage-independent growth, and invasion, respectively, of U251 and U373 cells. Data are representative of at least three independent experiments. # P < 0.05 versus Lenti-GFP-transduced group and non-transfected control group (n = 3) Figure 2B , knockdown of PEBP4 significantly suppressed the colony forming capacity of glioma cells, compared with that observed in the control groups.
Because cell invasion is an important process in tumor metastasis, we next performed a Transwell assay to investigate the role of PEBP4 in glioma cell invasion. A significantly lower number of invading U251 or U373 cells was observed after cells were transduced with LentishPEBP4 ( Figure 2C ). These results suggest that PEBP4 is essential for glioma cell proliferation and invasive potential in vitro.
| PEBP4 knockdown induces glioma cell apoptosis
To further determine the role of PEBP4 in glioma cell apoptosis, which is an important cellular event in glioma therapy, a flow cytometric assay was performed in Lenti-shPEBP4-transduced U251 and U373 cells.
The results showed that knockdown of PEBP4 resulted in significantly increased apoptotic rates of 15.74 ± 0.26% and 16.83 ± 0.53% in U251 and U373 cells, respectively, compared with those of control groups | 139 (Figure 3A) , suggesting that knockdown of PEBP4 promotes glioma cell apoptosis and thus reduces glioma cell survival.
| PEBP4 knockdown suppresses glioma growth in vivo
To determine the function of PEBP4 in tumor growth in vivo, LentishPEBP4-transfected U251 or U373 cells were injected into nude mice. 
| PEBP4 modulates ERK1/2 signaling
To examine the molecular mechanism underlying the effects of PEBP4 knockdown on glioma cell behaviors and the expression of related genes, we examined the relationship between PEBP4 downregulation and ERK1/2 signaling in the RAF1-MEK-ERK pathway, which is negatively modulated by the PEBP family. [10] [11] [12] [13] As shown in Figure 5A , knockdown of PEBP4 significantly increased the levels of phosphorylated ERK1/2 (p-ERK1/2), suggesting that PEBP4 is an upstream modulator of ERK1/2 signaling. In addition, when U251 and U373 cells were treated with U0126 ( Figure 5B ), the expression of anti-apoptotic Bcl-2 was upregulated whereas pro-apoptotic caspase-3 was downregulated. These results were contrary to the effects of PEBP4 knockdown on glioma cells without U0126 treatment, indicating that mediation of ERK1/2 signaling is essential in the function of PEBP4.
| ERK1/2 inhibitor reverses the effects of PEBP4 knockdown on glioma cell proliferation and apoptosis
To further confirm the role of the PEBP4-ERK1/2 axis in glioma cell behaviors, MTT and flow cytometric assays were performed in LentishPEBP4-expressing glioma cells with U0126 treatment. As shown in Figure 5C , compared with vehicle treatment, U0126 treatment promoted the proliferation of U251 and U373 cells, independent of the level of PEBP4 expression. This shows that U0126 treatment significantly decreased the apoptotic rates in U251 and U373 cells ( Figure 5D ). These results suggest that the PEBP4-ERK1/2 axis is critically required for glioma cell behaviors like proliferation and apoptosis.
| DISCUSSION
Expression of PEBP4 is upregulated in a variety of human cancers, and overexpression of PEBP4 not only promotes cancer cell proliferation and invasion, but also protects cancer cells against apoptosis. [19] [20] [21] [22] [23] [24] [25] In our previous research, we demonstrated that PEBP4 is overexpressed in tumor tissues at both the mRNA and protein levels compared to levels in non-neoplastic brain tissues, and PEBP4 upregulation is correlated with the risk of developing high-grade gliomas. In addition, high expression of PEBP4 has been identified as an independent predictor for poor prognosis of patients with gliomas. 17 Therefore, targeting PEBP4 represents a potential therapeutic intervention in glioma treatment. In the present study, lentiviral vector-mediated stable silencing of PEBP4 inhibited glioma cell proliferation, invasion, and colony forming ability while inducing cell apoptosis in vitro (Figures 2 and 3A) , as well as suppressing tumor growth in vivo ( Figure 3B ). These findings suggest that PEBP4 expression is essential for glioma cell growth, and thus, PEBP4 may be used as a novel target for glioma therapy in the future. It has been reported that IOI-42, a Cell cycle progression is a prerequisite of cancer cell growth. Rb protein inhibits cell growth by preventing S-phase entry during the cell cycle. 26 Certain cyclin D-dependent kinases catalyze the hyperphosphorylation of Rb, resulting in blockage of the suppressive actions of Rb on cell cycle and promotion of cell cycle progression. 27, 28 On the other hand, loss of the epithelial-mesenchymal transition marker Ecadherin and overexpression of neural-cadherin marker N-cadherin may lead to cell migration and invasion, which are important processes in cancer progression. 29 In the present study, we investigated whether PEBP4 regulates the expression of these cell cycle-related proteins as well as the apoptosis-associated proteins Bcl-2 and caspase-3. Our results demonstrate that the expression levels of p-RB, cyclin D1, and Bcl-2 were significantly downregulated following knockdown of PEBP4, whereas E-cadherin and caspase-3 were upregulated (Figure 4) , suggesting that these proteins are possible downstream targets of PEBP4. Meanwhile, we found that cleaved caspase-3 (c-caspase-3)
was downregulated while caspase-3 was upregulated, which suggests Previous research has suggested that inactivated ERK1/2 signaling can suppress apoptosis in prostate and ovarian cancer cells, 18, 22 although in results for other cancers, such as gastric cancer, downregulation of ERK1/2 had a certain pro-apoptotic effect. Our study also revealed that ERK1/2 signaling activity is enhanced by PEBP4 knockdown ( Figure 5 ), which is consistent with previous findings that PEBP4 overexpression inhibits ERK1/2 activation in prostate cancer cells. 18 On the other hand, inhibition of ERK1/2 signaling could reverse the PEBP4 knockdown-mediated effects ( Figure 5 ), indicating that knockdown of PEBP4 regulates glioma cell growth at least partially via ERK1/2 signaling. Previous studies showed that PEBP4 can translocate from lysosomes to the membrane and co-localize with Raf-1 and MEK1, which are upstream activators of ERK1/2 in response to apoptotic stimuli, and the conserved region of PE-binding domain appears to play a vital role in this biological activity of PEBP4 in breast cancer cells. 24 In addition, it is well established that PEBP4 resists prostate cancer cells apoptosis by activating PI3K/AKT signaling pathway and deactivating ERK1/2 pathway, and the effector process occurs downstream of caspase-8 and at the level of BID cleavage, and that PEBP4-regulated ERK1/2 deactivation was upstream of PI3K/ AKT activation. 18 This suggests that PEBP4 may be one of the factors mediating the crosstalk between the ERK1/2 and PI3K/AKT signaling pathways in cancer development.
In summary, in the present study, we demonstrated that PEBP4 is a novel and important modulator of glioma cell behaviors, including proliferation, invasion, and tumor growth, which provides a valuable clue for exploring effective treatment options for glioma therapy.
Whether the pharmacological effect of anti-glioma drugs such as temozolomide (TMZ) is achieved by inhibiting PEBP4 expression will be investigated in future studies.
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